Background: The global trend toward delayed childbearing has led to an increased use of fertility treatment, including in vitro fertilization (IVF) and hormonal medications. Concerns regarding the potential impact of these interventions on breast cancer risk, particularly among high-risk women with a pathogenic variant in the BRCA1 or BRCA2 genes remains an important clinical concern. Methods: We conducted a matched case–control analysis of women carrying a pathogenic or likely pathogenic variant in BRCA1 or BRCA2 enrolled in a longitudinal, international study. The analysis included 4,145 women with invasive breast cancer (cases) and 4,145 matched controls without breast cancer. Data on infertility and use of fertility treatments was collected by a research questionnaire. Conditional logistic regression was used to estimate the odds ratios (ORs) and 95% confidence intervals (CIs) for the association between infertility, fertility medications, and IVF, with the risk of breast cancer. Multivariable models were adjusted for parity and oral contraceptive use. Results: Among the 8,290 participants, 12% reported a history of infertility, 5% had used fertility medication, and 1% had undergone IVF. There was no statistically significant association between a history of infertility (OR = 0.96; 95% CI 0.84–1.10), use of any type of fertility medication (OR = 1.10; 95% CI 0.90–1.34), or IVF specifically (OR = 1.15; 95% CI 0.76–1.73) and the risk of BRCA-breast cancer. Findings were similar in the adjusted analyses. Conclusions: Findings from this large, international study found no evidence for an association between infertility or fertility treatment and the risk of breast cancer among BRCA1 or BRCA2 carriers. Although based on low rates of exposure, these findings provide some reassurance to BRCA carriers considering fertility treatment. Future studies evaluating impact of contemporary protocols are needed.

Seca, M., Gronwald, J., Huzarski, T., Glass, K., Aeilts, A., Kim, R., et al. (2025). Treatment of infertility and risk of breast cancer among women with a BRCA pathogenic variant: a matched case-control study. BMC CANCER, 25(1) [10.1186/s12885-025-15146-0].

Treatment of infertility and risk of breast cancer among women with a BRCA pathogenic variant: a matched case-control study

Fruscio R.;
2025

Abstract

Background: The global trend toward delayed childbearing has led to an increased use of fertility treatment, including in vitro fertilization (IVF) and hormonal medications. Concerns regarding the potential impact of these interventions on breast cancer risk, particularly among high-risk women with a pathogenic variant in the BRCA1 or BRCA2 genes remains an important clinical concern. Methods: We conducted a matched case–control analysis of women carrying a pathogenic or likely pathogenic variant in BRCA1 or BRCA2 enrolled in a longitudinal, international study. The analysis included 4,145 women with invasive breast cancer (cases) and 4,145 matched controls without breast cancer. Data on infertility and use of fertility treatments was collected by a research questionnaire. Conditional logistic regression was used to estimate the odds ratios (ORs) and 95% confidence intervals (CIs) for the association between infertility, fertility medications, and IVF, with the risk of breast cancer. Multivariable models were adjusted for parity and oral contraceptive use. Results: Among the 8,290 participants, 12% reported a history of infertility, 5% had used fertility medication, and 1% had undergone IVF. There was no statistically significant association between a history of infertility (OR = 0.96; 95% CI 0.84–1.10), use of any type of fertility medication (OR = 1.10; 95% CI 0.90–1.34), or IVF specifically (OR = 1.15; 95% CI 0.76–1.73) and the risk of BRCA-breast cancer. Findings were similar in the adjusted analyses. Conclusions: Findings from this large, international study found no evidence for an association between infertility or fertility treatment and the risk of breast cancer among BRCA1 or BRCA2 carriers. Although based on low rates of exposure, these findings provide some reassurance to BRCA carriers considering fertility treatment. Future studies evaluating impact of contemporary protocols are needed.
Articolo in rivista - Articolo scientifico
BRCA1; BRCA2; Breast cancer; Infertility; IVF;
English
10-nov-2025
2025
25
1
1740
open
Seca, M., Gronwald, J., Huzarski, T., Glass, K., Aeilts, A., Kim, R., et al. (2025). Treatment of infertility and risk of breast cancer among women with a BRCA pathogenic variant: a matched case-control study. BMC CANCER, 25(1) [10.1186/s12885-025-15146-0].
File in questo prodotto:
File Dimensione Formato  
Seca et al-2025-BMC Cancer-VoR.pdf

accesso aperto

Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Licenza: Creative Commons
Dimensione 988.23 kB
Formato Adobe PDF
988.23 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/600083
Citazioni
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
Social impact